Jennifer Kayden Lee Sells 1,447 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Jennifer Kayden Lee sold 1,447 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $59.43, for a total transaction of $85,995.21. Following the completion of the sale, the executive vice president now owns 4,038 shares of the company’s stock, valued at $239,978.34. The trade was a 26.38 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Jennifer Kayden Lee also recently made the following trade(s):

• On Monday, November 11th, Jennifer Kayden Lee sold 66,861 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $66.33, for a total transaction of $4,434,890.13.

Rhythm Pharmaceuticals Stock Performance

Shares of NASDAQ RYTM opened at $61.02 on Thursday. The firm has a 50 day moving average price of $57.37 and a 200 day moving average price of $53.19. The stock has a market cap of $3.75 billion, a P/E ratio of -14.09 and a beta of 2.14. Rhythm Pharmaceuticals, Inc. has a 52-week low of $35.17 and a 52-week high of $68.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.07. The business had revenue of $33.20 million during the quarter, compared to analysts’ expectations of $32.52 million. Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The firm’s quarterly revenue was up 47.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.76) EPS. Analysts predict that Rhythm Pharmaceuticals, Inc. will post -4.33 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Loomis Sayles & Co. L P acquired a new stake in shares of Rhythm Pharmaceuticals during the third quarter worth about $33,353,000. Alkeon Capital Management LLC raised its holdings in Rhythm Pharmaceuticals by 16.8% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,167,700 shares of the company’s stock worth $61,176,000 after buying an additional 167,700 shares during the period. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in Rhythm Pharmaceuticals by 14.9% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,111,043 shares of the company’s stock valued at $58,208,000 after buying an additional 143,800 shares in the last quarter. Barclays PLC lifted its stake in Rhythm Pharmaceuticals by 79.6% in the third quarter. Barclays PLC now owns 106,397 shares of the company’s stock valued at $5,574,000 after buying an additional 47,166 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. boosted its holdings in shares of Rhythm Pharmaceuticals by 1.9% in the third quarter. Frazier Life Sciences Management L.P. now owns 2,416,952 shares of the company’s stock valued at $126,624,000 after buying an additional 45,648 shares during the period.

Analyst Ratings Changes

Several research firms have recently commented on RYTM. Bank of America lifted their target price on Rhythm Pharmaceuticals from $48.00 to $52.00 and gave the company a “neutral” rating in a research note on Monday, October 14th. TD Cowen lifted their price objective on Rhythm Pharmaceuticals from $55.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Guggenheim began coverage on shares of Rhythm Pharmaceuticals in a research report on Monday, October 21st. They set a “buy” rating and a $70.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $69.00 price target on shares of Rhythm Pharmaceuticals in a research report on Monday, December 23rd. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $80.00 price objective on shares of Rhythm Pharmaceuticals in a report on Tuesday, November 19th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $68.09.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.